Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates through two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise software that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing programs or systems. The company also provides RxCompanion, a cloud-based MTM software platform designed to aid in the identification and resolution of medication and other health related problems; TruChart, a web-based electronic health record for Programs of All-Inclusive Care for the Elderly (PACE) organizations; PACElogic, which delivers real-time sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state required reporting. In addition, the company offers DoseMeRx, a decision support software; PrescribeWellness, a patient engagement center platform; and clinical pharmacist collaboration, prescription fulfillment and reminder packaging, and pharmacy cost management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2020, it served approximately 130 healthcare organizations; and 280 health plans and approximately 14,000 retail pharmacies. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.
IPO Year: 2016
Exchange: NASDAQ
Website: tabularasahealthcare.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2023 | $7.00 → $10.00 | Market Perform → Outperform | SVB Securities |
| 3/2/2022 | $30.00 → $15.00 | Buy | Benchmark |
| 2/28/2022 | $23.00 → $11.00 | Market Perform | SVB Leerink |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Robert W. Baird |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Baird |
| 12/2/2021 | $13.00 | Hold | Jefferies |
| 11/8/2021 | $70.00 → $23.00 | Outperform | RBC Capital |
| 11/8/2021 | $40.00 → $23.00 | Market Perform | SVB Leerink |
| 9/24/2021 | $49.00 → $40.00 | Market Perform | SVB Leerink |
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
15-12G - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
Appoints Brian Adams as President and Chief Executive Officer and a Member of the Board of Directors, Effective Immediately Appoints Richard W. Rew II as Chief Legal Officer and Corporate Secretary Announces Preliminary Unaudited First Quarter 2023 Revenue Exceeding Guidance MOORESTOWN, N.J., April 13, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of Brian Adams as President and Chief Executive Officer. Mr. Adams, who was serving as TRHC's interim Chief Executive Officer since September 2022 and previously served as the Company's Co-Pre
MOORESTOWN, N.J., Nov. 1, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of April D. Gill as Chief Commercial Officer. Ms. Gill has more than 20 years of experience in healthcare with a proven track record exceeding client satisfaction, sales, and profitability goals. In this newly created role, Ms. Gill will oversee development and execution of TRHC's commercialization with broad responsibility for strategy, product, marketing, communication
Drs. Calvin H. Knowlton and Orsula V. Knowlton to retire from the Company Co-President Brian Adams Named Interim CEO Director Michael Purcell Named Independent Board Chairman MOORESTOWN, N.J., Sept. 14, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced that co-founders Dr. Calvin H. Knowlton, BScPharm, MDiv, PhD, ScD (hon), Chief Executive Officer and Board Chairman, and Dr. Orsula V. Knowlton, PharmD, MBA, Co-President and Chief Marketing and New Business Development Officer, will retire from TRHC and step down as members of the Board of Directors, effective immediately. Dir
Agreement Also Provides for Enhancements to the Company's Corporate Governance, Including a Commitment to Propose a De-Classification of the Board at the 2023 Annual Meeting MOORESTOWN, N.J., Sept. 14, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today announced a cooperation agreement with Indaba Capital Management, L.P. ("Indaba"), the Company's largest stockholder with an approximately 25% equity stake. Pursuant to the cooperation agreement,
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13G/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13G/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13G/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13D - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Veritiv Corporation (NYSE:VRTV) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of VRTV to an affiliate of Clayton, Dubilier & Rice, LCC for $170.00 per share in cash for each share of VRTV common stock owned. If you are a VRTV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Fiesta Restaurant Group, Inc. (NASDAQ:FRGI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary dutie
Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million
$10.50 Per Share All-Cash Transaction Represents a Significant Premium for Tabula Rasa Stockholders Combination of Two Highly Complementary Companies to Benefit Patients, Providers and Payers with First of its Kind Risk Management Platform in Pharmacy Care Expands the Reach of Tabula Rasa's MedWise Technology Platform to Multiple Provider and Payer Markets MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® ("TRHC," "Tabula Rasa" or the "Company") (NASDAQ:TRHC), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today announced it has entered into a definitive agreement (the "Agreement") to be acquired by Nauti
MOORESTOWN, N.J., July 25, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2023 financial results Tuesday, August 8, 2023 at 8:30 a.m. EDT. The Company's financial results for the second quarter 2023 ended June 30, 2023, will be released after the close of the market Monday, August 7, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in numbe
MOORESTOWN, N.J., May 17, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today announced that Mountain Empire PACE, a Program of All-Inclusive Care for the Elderly (PACE) in rural Virginia, has signed agreements with TRHC for personalized pharmacy services and pharmacy benefit management, expanding their existing partnership. TRHC's comprehensive pharmacy services provide Mountain Empire PACE with individualized medication risk management, round
First Quarter Results Show Benefits of Consistent Execution on Financial and Strategic Objectives First Quarter Revenue Growth of 32% Compared to First Quarter 2022 Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance MOORESTOWN, N.J., May 8, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first quarter ended March 31, 2023. Highlights from the first quarter ended March 31, 2023, include: First quarter revenu
MOORESTOWN, N.J., April 26, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its first quarter 2023 financial results Tuesday, May 9, 2023 at 8:30 a.m. EDT. The Company's financial results for the first quarter 2023 ended March 31, 2023, will be released after the close of the market Monday, May 8, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in number alon
Appoints Brian Adams as President and Chief Executive Officer and a Member of the Board of Directors, Effective Immediately Appoints Richard W. Rew II as Chief Legal Officer and Corporate Secretary Announces Preliminary Unaudited First Quarter 2023 Revenue Exceeding Guidance MOORESTOWN, N.J., April 13, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of Brian Adams as President and Chief Executive Officer. Mr. Adams, who was serving as TRHC's interim Chief Executive Officer since September 2022 and previously served as the Company's Co-Pre
Incremental $25 Million of Capital to be Returned as Special Cash Dividend Delivering In Aggregate $50 Million Special Cash Dividend Payable in Q2 2023 Cynthia Paul and Ron Mitchell Appointed to Board of Directors; Company to Pursue Board Declassification by 2026 Annual Meeting Enters into Cooperation Agreement with Indaba Capital Management ON24 (NYSE:ONTF) ("ON24" or the "Company"), a leading sales and marketing platform for B2B digital engagement, today announced that its Board of Directors (the "Board") has authorized an expansion of its recently announced capital return program and a series of governance enhancements. $125 Million Capital Return Authorization The ON24 Board of Dir
Fourth Quarter Concludes Successful Transformational Year, With Company Sharpening Focus and Laying a Foundation for Sustainable, Profitable Growth Recently Completed Sales of SinfoníaRx and DoseMe Shares Full Year 2023 Revenue Guidance and Adjusted EBITDA Guidance MOORESTOWN, N.J., March 6, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the fourth quarter and full year ended December 31, 2022. Highlights from fourth
SVB Securities upgraded Tabula Rasa HealthCare from Market Perform to Outperform and set a new price target of $10.00 from $7.00 previously
Benchmark reiterated coverage of Tabula Rasa HealthCare with a rating of Buy and set a new price target of $15.00 from $30.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $11.00 from $23.00 previously
Robert W. Baird downgraded Tabula Rasa HealthCare from Outperform to Neutral and set a new price target of $11.00 from $24.00 previously
Baird downgraded Tabula Rasa HealthCare from Outperform to Neutral and set a new price target of $11.00 from $24.00 previously
Jefferies initiated coverage of Tabula Rasa HealthCare with a rating of Hold and set a new price target of $13.00
RBC Capital reiterated coverage of Tabula Rasa HealthCare with a rating of Outperform and set a new price target of $23.00 from $70.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $23.00 from $40.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $40.00 from $49.00 previously
Robert W. Baird initiated coverage of Tabula Rasa HealthCare with a rating of Outperform and set a new price target of $53.00
Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million
MOORESTOWN, N.J., July 25, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2023 financial results Tuesday, August 8, 2023 at 8:30 a.m. EDT. The Company's financial results for the second quarter 2023 ended June 30, 2023, will be released after the close of the market Monday, August 7, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in numbe
First Quarter Results Show Benefits of Consistent Execution on Financial and Strategic Objectives First Quarter Revenue Growth of 32% Compared to First Quarter 2022 Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance MOORESTOWN, N.J., May 8, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first quarter ended March 31, 2023. Highlights from the first quarter ended March 31, 2023, include: First quarter revenu
MOORESTOWN, N.J., April 26, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its first quarter 2023 financial results Tuesday, May 9, 2023 at 8:30 a.m. EDT. The Company's financial results for the first quarter 2023 ended March 31, 2023, will be released after the close of the market Monday, May 8, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in number alon
Fourth Quarter Concludes Successful Transformational Year, With Company Sharpening Focus and Laying a Foundation for Sustainable, Profitable Growth Recently Completed Sales of SinfoníaRx and DoseMe Shares Full Year 2023 Revenue Guidance and Adjusted EBITDA Guidance MOORESTOWN, N.J., March 6, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the fourth quarter and full year ended December 31, 2022. Highlights from fourth
NEW YORK, March 3, 2023 /PRNewswire/ -- Cureatr, a national, value-based medication management services company improving quality and reducing total cost of care, announces it has acquired the SinfoníaRx business, an industry leader in medication therapy management (MTM), from Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications. This acquisition will round out Cureatr's existing clinical pharmacy services to include MTM and expand the company's scale with a larger team of clinical pharmacists, pharmacy tech
MOORESTOWN, N.J., March 2, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced that it completed the sale of its SinfoníaRx business to Cureatr, following the sale of its DoseMeRx business to an affiliate of Fairlong Capital LLC earlier this year. The combined proceeds are $11 million. "The successful sale of these two businesses, along with the sale of PrescribeWellness in August 2022, completes the strategic divestitures that we announced last year, advancing our comm
MOORESTOWN, N.J., Feb. 21, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its fourth quarter and full year 2022 financial results Tuesday, March 7, 2023 at 8:30 a.m. EDT. The Company's financial results for the fourth quarter and full year ended December 31, 2022, will be released after the close of the market Monday, March 6, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to
Revenue from continuing operations of $77.1 million increased 14% vs. a year agoGAAP net loss from continuing operations of $25.9 million vs. $11.8 million a year agoAdjusted EBITDA from continuing operations of $2.1 million vs. $3.1 million a year agoCash of $80.8 million as of September 30, 2022, vs. $26.5 million as of June 30, 2022MOORESTOWN, N.J., Nov. 3, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the third quarter ended September 30, 2022.
MOORESTOWN, N.J., Oct. 20, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), will hold a conference call and webcast to discuss its third quarter 2022 operating results Friday, November 4, 2022 at 8:30 a.m. EDT. The Company's financial results for the third quarter ended September 30, 2022, will be released after the close of the market Thursday, November 3, 2022. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in n
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P 500, also rose, gaining, 0.65% to 4,507.13. Check This Out: Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Financials shares jumped by 1.4% on Monday. In trading on Monday, information technology shares fell 0.1%. Top Headline Henry Schein Inc (NASDAQ:HSIC) reported better-than-expected second-quarter earnings. Henry Schein posted quarterly sales of $3.10 billion, slightly missing the consensus of $3.11 billion, up 2.3% Y/Y, including 0.2%
Nautic Partners agreed to acquire Tabula Rasa HealthCare Inc (NASDAQ:TRHC) for $10.50 in cash per share and combine with ExactCare Pharmacy, a portfolio company of Nautic. The all-cash transaction values Tabula Rasa at approximately $570 million including net debt of approximately $262 million on an enterprise value basis. Following the closing of the transaction, John Figueroa, ExactCare's current Executive Chairman, will assume the role of Chairman and CEO of the combined company. The transaction is expected to close during Q4 of 2023. The deal expands the reach of Tabula Rasa's MedWise technology platform to multiple provider and payer markets. Tabula Rasa HealthCare reported Q2 adj
Gainers Vistagen Therapeutics (NASDAQ:VTGN) shares rose 871.4% to $16.32 during Monday's regular session. Trading volume for this security as of 13:30 EST is 40.9 million, which is 18764.9% of its average full-day volume over the last 100 days. The company's market cap stands at $130.3 million. Nektar Therapeutics (NASDAQ:NKTR) shares increased by 89.89% to $1.01. The current volume of 138.1 million shares is 4109.5% of Nektar Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $191.3 million. Tabula Rasa HealthCare (NASDAQ:TRHC) stock increased by 30.84% to $10.24. Trading volume for Tabula Rasa Hea
Gainers Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints. Save Foods, Inc. (NASDAQ:SVFD) gained 140.6% to $1.54 on abnormally-high volume. Poseida Therapeutics, Inc. (NASDAQ:PSTX) jumped 53% to $2.49. Astellas and Poseida Therapeutics announced strategic investment to support Poseida's commitment to redefining cancer cell therapy. Missfresh Limited (NASDAQ:MF) shares climbed 46.5% to $2.90 on continued upward momentum after the company last week announced entry of share purchase agreements for financi
William Blair analyst Ryan Daniels downgrades Tabula Rasa HealthCare (NASDAQ:TRHC) from Outperform to Market Perform.
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss at $0.44 per share on revenue of $153.69 million. • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.09 per share on revenue of $289.53 million. • Hawaiian Electric Indus (NYSE:HE) is estimated to report quarterly earnings at $0.52 per share on revenue of $845.37 million. • Gogo (NASDAQ:GOGO) is projected to report quarterly earnings at $0.13 per share on revenue of $103.25 million. • BioNTech (NASDAQ:BNTX) is estimated to report quarterly loss at $0.75 per share on revenue of $944.34 million. • AG Mortgage IT (NYSE:MITT) is expected to report quarterly earnings at $
U.S. stocks were higher midway through trading, with the Dow Jones gaining more than 300 points on Monday. The Dow traded up 0.88% to 35,374.41 while the NASDAQ rose 0.12% to 13,925.71. The S&P 500, also rose, gaining, 0.56% to 4,502.9. Check This Out: Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Financials shares jumped by 1.2% on Monday. In trading on Monday, information technology shares rose by just 0.1%. Top Headline Henry Schein Inc (NASDAQ:HSIC) reported better-than-expected second-quarter earnings. Henry Schein posted quarterly sales of $3.10 billion, slightly missing the consensus of $3.11 billion, up 2.3% Y/Y, including 0.2
Gainers Vistagen Therapeutics (NASDAQ:VTGN) stock increased by 187.5% to $4.83 during Monday's pre-market session. The market value of their outstanding shares is at $38.5 million. Nektar Therapeutics (NASDAQ:NKTR) stock moved upwards by 33.87% to $0.71. The company's market cap stands at $134.9 million. Tabula Rasa HealthCare (NASDAQ:TRHC) stock increased by 32.05% to $10.34. The market value of their outstanding shares is at $277.6 million. The company's, Q2 earnings came out today. T2 Biosystems (NASDAQ:TTOO) stock moved upwards by 25.92% to $0.31. The market value of their outstanding shares is at $91.3 million. As per the press release, Q2 earnings came out today. Gracell Biotechno
Tabula Rasa HealthCare (NASDAQ:TRHC) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.14) by 121.43 percent. This is a 105.66 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $90.04 million which beat the analyst consensus estimate of $88.82 million by 1.37 percent. This is a 24.02 percent increase over sales of $72.60 million the same period last year.